Frazier Life Sciences Public Fund, L.P.
Known title: 10% OwnerCIK: 0001863769
Frazier Life Sciences Public Fund, L.P.'s purchase track record
Frazier Life Sciences Public Fund, L.P. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/23/2021 | VRDN | $2.20M | +49.4% | +38.9% | +1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| VRDN | ▲ Buy | Open Market | 200,000 | $2.2M | 9/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
VRDN Draws Institutional Interest; Set for Wells Fargo Healthcare Conference
Viridian Therapeutics has attracted attention as a healthcare specialist identified it among four biotech stocks of interest, according to Benzinga. The company is scheduled to present at the Wells Fargo Healthcare Conference, a routine industry event for biotech firms seeking investor engagement. The stock is currently trading within its 52-week range of $13.18 to $34.29, while analysts maintain an average price target of $36.62 based on 16 estimates.
VRDN Draws Institutional Interest; Set for Wells Fargo Healthcare Conference. Viridian Therapeutics has attracted attention as a healthcare specialist identified it among four biotech stocks of interest, according to Benzinga. The company is scheduled to present at the Wells Fargo Healthcare Conference, a routine industry event for biotech firms seeking investor engagement. The stock is currently trading within its 52-week range of $13.18 to $34.29, while analysts maintain an average price target of $36.62 based on 16 estimates.